Compare Becton Dickinson and Co (BDX) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Bristol-Myers Squibb Co — how do they compare? Becton Dickinson and Co trades at $180.75 (market cap $49.41B), while Bristol-Myers Squibb Co trades at $63.57 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.6× Becton Dickinson and Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BDX | BMY | |
|---|---|---|
Market Cap | $49.41B | $129.94B |
Sector | Health | Health |
52-Week High | $185.39 | $65.89 |
52-Week Low | $138.62 | $42.60 |
Enterprise Value | $65.51B | $163.92B |
Dividend Yield | 2.32% | 3.96% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
